Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.85 |
| ▸ | MAOA | P21397 | 4/20 | 0.85 |
| ▸ | F10 | P00742 | 11/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | SDHA | P31040 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CALML3 | P27482 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040542 | 1.00 | MAOB (0.85) | MAOBMAOAF10PTGS1SDHA | |
| SCHEMBL6040231 | 0.96 | MAOB (0.80) | MAOBMAOAF10PTGS1SDHA | |
| SCHEMBL6040229 | 0.96 | MAOB (0.80) | MAOBMAOAF10PTGS1SDHA | |
| SCHEMBL7161225 | 0.92 | MAOB (0.79) | MAOBMAOAF10PTGS1SDHA | |
| SCHEMBL7161224 | 0.92 | MAOB (0.79) | MAOBMAOAF10PTGS1SDHA | |
| Sutezolid SCHEMBL29757643 | 0.92 | MAOB (1.00) | MAOBMAOAF10PTGS1SDHA | |
| SCHEMBL7846257 | 0.92 | MAOB (0.79) | MAOBMAOAF10PTGS1SDHA | |
| Sutezolid SCHEMBL2152517 | 0.92 | MAOB (1.00) | MAOBMAOAF10PTGS1SDHA | |
| SCHEMBL7846260 | 0.92 | MAOB (0.79) | MAOBMAOAF10PTGS1SDHA | |
| Sutezolid SCHEMBL2152519 | 0.92 | MAOB (1.00) | MAOBMAOAF10PTGS1SDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984947-B8 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-0984947-B1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | UPJOHN CO (US) | 2005-04-20 | — | — | EP | claimed |
| EP-1274426-B1 | USE OF THIOAMIDE OXAZOLIDINONES FOR THE TREATMENT OF BONE RESORPTION AND OSTEOPOROSIS | UPJOHN CO (US) | 2004-04-14 | — | — | EP | claimed |
| US-20020016323-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | PHARMACIA & UPJOHN COMPANY | 2002-02-07 | — | — | US | claimed |
| US-20010041728-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | HESTER JACKSON B (US) | 2001-11-15 | — | — | US | claimed |
| US-6255304-B1 | AIDS THERAPY | PHARMACIA & UPJOHN COMPANY | 2001-07-03 | — | — | US | claimed |
| EP-0984947-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054161-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-03 | — | — | WO | claimed |
| EP-1451164-A2 | AMIDE DERIVATIVES HAVING IMPROVED SOLUBILITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1274426-B1 | USE OF THIOAMIDE OXAZOLIDINONES FOR THE TREATMENT OF BONE RESORPTION AND OSTEOPOROSIS | UPJOHN CO (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006440-A2 | AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020016323-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | PHARMACIA & UPJOHN COMPANY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041728-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | OXA1L, MRPL21, TOP1 | MAOB 2998/4885MAOA 3306/4885F10 3383/4885 |
| US-20020016323-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | OXA1L, MRPL21, TOP1 | MAOB 2998/4885MAOA 3306/4885F10 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.